- Biohaven looks to take on Lilly in the muscle-sparing obesity spaceThey say that the way to make money in a gold rush is to open a shop selling picks and shovels. By the same token, perhaps companies can profit from the GLP-1 boom by developing ...Endpoints · 17d ago↗ source
- STAT+: Europe will accelerate its review of RevMed’s drugKailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The ReadoutSTAT · 17d ago↗ source
- STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam TherapeuticsPrime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.STAT